One study indicated that methylation of CDKN2B was present in 30.8% (43) of ovarian cancer cases and was associated with disease progression, whereas other studies showed that methylation of CDKN2B is a rare event (18,37). Here, CDKN2B is linked to ovarian carcinoma.